{
    "ticker": "CRMD",
    "name": "CorMedix Inc.",
    "description": "CorMedix Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutic products for the prevention and treatment of infectious and inflammatory diseases. Founded in 2006 and headquartered in Bridgewater, New Jersey, CorMedix focuses on providing patients with effective solutions that improve their quality of life. The company\u2019s lead product, Neutrolin, is a novel catheter lock solution designed to prevent catheter-related infections in patients undergoing hemodialysis. Neutrolin has received marketing authorization in Europe and is currently undergoing clinical trials in the United States to secure FDA approval. In addition to Neutrolin, CorMedix is exploring other potential therapeutic applications and product candidates aimed at addressing significant unmet medical needs in various therapeutic areas. The company's commitment to innovation and patient care drives its research and development efforts, with a goal of delivering impactful therapies that enhance patient safety and outcomes. CorMedix is strategically positioned to make a meaningful difference in the healthcare landscape, focusing on prevention and improved management of chronic conditions where infections play a critical role.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Bridgewater, New Jersey, USA",
    "founded": "2006",
    "website": "https://www.cormedix.com",
    "ceo": "Katherine D. Stueland",
    "social_media": {
        "twitter": "https://twitter.com/CorMedix",
        "linkedin": "https://www.linkedin.com/company/cormedix/"
    },
    "investor_relations": "https://www.cormedix.com/investors",
    "key_executives": [
        {
            "name": "Katherine D. Stueland",
            "position": "CEO"
        },
        {
            "name": "Michael E. D. McCarthy",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutic Products",
            "products": [
                "Neutrolin"
            ]
        }
    ],
    "seo": {
        "meta_title": "CorMedix Inc. | Innovative Biopharmaceutical Solutions",
        "meta_description": "Explore CorMedix Inc., a biopharmaceutical company focused on innovative therapies for preventing infections and treating chronic conditions. Learn about their lead product, Neutrolin.",
        "keywords": [
            "CorMedix",
            "Biopharmaceuticals",
            "Neutrolin",
            "Infectious Diseases",
            "Chronic Conditions",
            "Catheter-related Infections"
        ]
    },
    "faq": [
        {
            "question": "What does CorMedix focus on?",
            "answer": "CorMedix focuses on developing innovative therapeutic products for preventing and treating infectious and inflammatory diseases."
        },
        {
            "question": "What is Neutrolin?",
            "answer": "Neutrolin is a catheter lock solution designed to prevent catheter-related infections in patients undergoing hemodialysis."
        },
        {
            "question": "Where is CorMedix headquartered?",
            "answer": "CorMedix is headquartered in Bridgewater, New Jersey, USA."
        },
        {
            "question": "When was CorMedix founded?",
            "answer": "CorMedix was founded in 2006."
        }
    ],
    "competitors": [
        "CHRS",
        "CRIS",
        "NTRA",
        "PTCT"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "BMY",
        "GILD"
    ]
}